September 2022
Author Interview: Eduardo Mysler
Dr Eduardo Mysler, from the School of Medicine, University of Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Mysler discusses his recent paper 'Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.'
Discussing PsA: Episode 3
Join Professors Iain McInnes and Phillip Mease as well as Doctors Frank Behrens and Laura Coates as they discuss the latest top research in PsA. In this edition, our Steering Committee members look at three key papers published in August 2022. Our first paper aims to highlight the efficacy of secukinumab on Achilles’ tendon enthesitis in SpA patients by looking at a single tender point out of the six-point LEI. The second of today’s papers evaluates the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial. Finally, our third paper reports the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients. Everything discussed is available in a more detailed slide format in the publications section at imidforum.com.
August 2022
Author Interview: Ameen Jubber
Dr Ameen Jubber, specialist registrar in rheumatology at the University Hospitals of Leicester NHS Trust, in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Jubber discusses his recent editorial paper reviewing the evidence for VTE risk in JAKinibs, and whether this risk also extends to the second-generation JAKinibs.
Discussing Rheumatology: August 2022
Join Prof Iain McInnes as he reviews two interesting papers. The first covers new data from China on the first-in-human trial of KL130008. The second reports on the exposure-response analyses of filgotinib for dose confirmation. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at imidforum.com.
Author Interview: Kim Lauper
Dr Kim Lauper, from the Division of Rheumatology, Department of Internal Medicine and Department of Medicine, Faculty of Medicine, Geneva University Hospitals, Geneve, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this addition Dr Lauper discusses her latest paper; Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration.
Discussing axSpA: Episode 2
Join Prof. Baraliakos and Dr Mehta as they discuss the latest top research in axSpA. In this edition, our Steering Committee members look at three key papers published in July 2022. Our first paper investigated upadacitinib efficacy and safety in axSpA. The second of today’s looks at factors associated with drug-free remission in early onset axSpA patients. Finally, our third paper focuses on the association of bDMARD treatments with hospital acquired infections. Everything discussed is available in a more detailed slide format in the publications section at imidforum.com.